RECRUITING

Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This large real-world international prospective registry will provide a unique opportunity to comprehensively understand the contemporary management, clinical course and short as well as long-term outcomes of all Cardiogenic Shock (CS) patients cared for at four high volume dedicated shock care centers. As the first true North American multicenter CS collaborative with a uniform dedicated and comprehensive case report form, the high patient volumes and wide spectrum of clinical acuity seen at these institutions will provide valuable insight into the factors associated with adverse outcomes; and will serve as a blueprint for future clinical trial designs that may better inform clinical practice.

Official Title

Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

Quick Facts

Study Start:2022-05-25
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05185492

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Primary diagnosis of cardiogenic shock at time of index evaluation; including acute myocardial infarction- and acute decompensated heart failure-cardiogenic shock phenotypes
  2. * Patients with cardiac arrest complicating cardiogenic shock and those with massive pulmonary embolism with right ventricular cardiogenic shock will also be eligible for the registry
  1. * Patients with shock not due to primary cardiac etiology will be excluded. These include septic, hemorrhagic, and anaphylactic shock.

Contacts and Locations

Study Contact

John Kirk
CONTACT
801-585-2944
john.kirk@hsc.utah.edu

Principal Investigator

Stavros Drakos, M.D.
PRINCIPAL_INVESTIGATOR
University of Utah

Study Locations (Sites)

Cleveland Clinic Florida
Weston, Florida, 33331
United States
Inova Heart and Vascular Institute
Falls Church, Virginia, 22042
United States

Collaborators and Investigators

Sponsor: STAVROS G DRAKOS

  • Stavros Drakos, M.D., PRINCIPAL_INVESTIGATOR, University of Utah

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-25
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2022-05-25
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Cardiogenic Shock
  • Acute Myocardial Infarction